165 filings
Page 5 of 9
8-K
eqeyetw
20 Mar 20
Entry into a Material Definitive Agreement
4:13pm
8-K
jgcjg693
4 Mar 20
Regulation FD Disclosure
4:06pm
8-K
fn8p0 13cpga11ymv
13 Feb 20
PhaseBio Appoints Alex C. Sapir to Board of Directors
4:07pm
8-K
xyh3uk
11 Feb 20
PhaseBio Announces European Regulatory Update for PB2452
8:08am
8-K
1as0mvm wkv8v1xsy5uv
4 Feb 20
PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at 14th Pulmonary Vascular Research Institute World Congress
4:08pm
8-K
yjf35ge4mhpa3jd7hu
13 Jan 20
PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension
4:07pm
8-K
nlbypmy
10 Jan 20
PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452
9:07am
EFFECT
rfaakh86kk2a
9 Jan 20
Notice of effectiveness
12:15am
CORRESP
85kwwd89 5p6f
6 Jan 20
Correspondence with SEC
12:00am
UPLOAD
4odyofs1ie2v55zsfgf
3 Jan 20
Letter from SEC
12:00am
S-3
sfrxmfk6bf6w1kz
27 Dec 19
Shelf registration
5:28pm
8-K
zm20yaa
14 Nov 19
PhaseBio Reports Third Quarter 2019 Financial Results and Recent Corporate Progress
8:16am
8-K
w0ohls
15 Oct 19
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
8:03am
8-K
ygknxj0tqcuqfgxingb
24 Sep 19
PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
4:05pm
8-K
i0j8ddv j12f
14 Aug 19
Regulation FD Disclosure
12:00am
8-K
nynfg9b0
13 Aug 19
PhaseBio Reports Second Quarter 2019 Financial Results and Recent Corporate Progress
4:05pm
8-K
xa5 0ljvh13g
1 Jul 19
Other Events
8:02am
8-K
glqnl
17 Jun 19
Other Events
4:05pm